caa a22 4500 469121513 CHVBK 20180323133140.0 cr unu---uuuuu 170328e19920201xx s 000 0 eng 10.1007/BF02246260 doi (NATIONALLICENCE)springer-10.1007/BF02246260 Priest R. Academic Department of Psychiatry, St Mary's Hospital, Praed Street, W2 1NY, London, UK aut Moclobemide: a range of opportunities [Elektronische Daten] [R. Priest] Conclusions: Moclobemide is a powerful agent against depressive illness, whether unipolar or bipolar, agitated or retarded, psychotic or neurotic, with or without melancholia. It is active in the elderly as well as in younger adults, and it is effective in the presence or in the absence of benzodiazepines. As a novel, safe and clean drug it has great potential for exploratory use in other psychiatric disorders. It is promising in the attention deficit (hyperkinetic) syndrome of children, it appears to be useful in social phobia and it has produced exciting results in Alzheimer's disease. It will be of great interest to learn of the activity of moclobemide on depressive syndromes in other situations, e.g. Parkinson's disease, post-psychotic depression, or depression in children. It is also important to assess its effect in other non-psychotic mental illnesses, such as obsessive-compulsive disorder, panic disorder and other anxiety syndromes. Apart from its safety and its demonstrable efficacy as an antidepressant, there are features of moclobemide's mechanism of action that raise high hopes of still further novel effects. Since we have a drug that is specific in its action on the monoamine oxidase-A system, and whose structure and effects are quite different from other compounds in clinical use, we are justified in anticipating that a rich and varied range of opportunities will be revealed in the months and years to come. Springer-Verlag, 1992 Moclobemide nationallicence Depressive illness nationallicence Melancholia nationallicence Antidepressant nationallicence Monoamine oxidase-A nationallicence Psychopharmacology Springer-Verlag 106(1992-02-01), S140-S141 0033-3158 106<S140 1992 106 213 https://doi.org/10.1007/BF02246260 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02246260 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Priest R. Academic Department of Psychiatry, St Mary's Hospital, Praed Street, W2 1NY, London, UK aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106(1992-02-01), S140-S141 0033-3158 106<S140 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer